GenMark Diagnostics provides preliminary results for 2017

|About: GenMark Diagnostics, Inc. (GNMK)|By:, SA News Editor

GenMark Diagnostics (NASDAQ:GNMK) provides preliminary operational and financial results for FY 2017.

FY 2017 Total revenue of ~$52.5M, an increase of 7% over 2016.

Q4 Total revenue of ~$16M, up 8% over Q4 2016.

Placed 49 ePlex analyzers Q4.

Launched ePlex NP targeting customers with lower testing volumes, contributing to Q4 placements.

Initiated the first of three clinical trials for the ePlex BCID family of panels.

The company expects to issue full 2017 financial results and 2018 guidance in late February.

Subscribe for full text news in your inbox